ASH 2018 Tisagenlecleucel continues to show durable remissions in kids and young adults with stubborn form of leukaemia

ASH 2018: Tisagenlecleucel continues to show durable remissions in kids and young adults with stubborn form of leukaemia

15:05 EST 1 Dec 2018 | ecancermedicalscience

A single infusion of tisagenlecleucel in paediatric and young adult patients with relapsed or treatment-resistant acute lymphocytic leukaemia (ALL) continues to be highly effective in fighting cancer in most people, without the need for additional...

More From BioPortfolio on "ASH 2018: Tisagenlecleucel continues to show durable remissions in kids and young adults with stubborn form of leukaemia"